Core Viewpoint - Meili Tianyuan Healthcare (02373) expects to achieve a revenue of no less than RMB 3 billion in 2025, representing a growth of at least 16% compared to the same period in 2024, and an adjusted net profit of no less than RMB 380 million, reflecting a growth of at least 40% year-on-year [1] Group 1: Financial Projections - The company anticipates a net profit of no less than RMB 340 million in 2025, which is an increase of at least 34% compared to 2024 [1] - Revenue target for 2025 is set at no less than RMB 3 billion, indicating a growth of at least 16% from 2024 [1] - Adjusted net profit is projected to be no less than RMB 380 million, marking a growth of at least 40% year-on-year [1] Group 2: Reasons for Performance Improvement - Accelerated external expansion is a key driver, highlighted by the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong organic growth is noted, driven by an increase in brand momentum and customer numbers, leading to higher internal revenue growth and an increased proportion of high-margin medical business revenue [1] - The company emphasizes a dual strategy of "organic growth + external acquisitions" and aims to deepen its "dual beauty + dual healthcare" business model [1]
美丽田园医疗健康发盈喜 预期2025年经调整净利润不少于3.8亿元 同比增长不少于40%